Pavmed Inc.'s majority owned subsidiary, Lucid Diagnostics, entered into subscription agreements with investors for the sale of Series B-1 Preferred Stock, raising approximately $11.6 million.
AI Assistant
PAVMED INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.